A recently proposed model, the ‘Prediction Of Survival in Advanced Sorafenib‐treated HCC’ (PROSASH), provided individualized survival prediction with excellent risk group discrimination based on nine parameters (age, macrovascular invasion, extrahepatic spread, performance status, disease aetiology, albumin, creatinine, aspartate transaminase (AST) and AFP).21 The PROSASH model was built and validated on the data from patients treated with sorafenib in two clinical trials,22, 23 but has not yet been validated in patients treated in routine clinical practice. This evidence concerns the gene AFP and hepatocellular carcinoma.